iTeos Therapeutics (NASDAQ:ITOS) Receives “Outperform” Rating from Wedbush

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and autoimmune diseases. The company's lead product candidate is ITOS-101, an oral small molecule targeting the PI3K/AKT pathway in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

On February 24, 2022, Wedbush Securities initiated coverage on iTeos Therapeutics with an "Outperform" rating and a price target of $15.00 per share. The analysts at Wedbush cited the company's strong clinical data for ITOS-101 in DLBCL patients, as well as its potential to expand into other indications such as non-Hodgkin's lymphoma and multiple myeloma.

iTeos Therapeutics has also recently announced plans to initiate a phase 2 clinical trial of ITOS-101 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients who have failed prior therapies, including CAR-T cell therapy. The company expects to report top-line data from this trial in the second half of 2022.

Overall, Wedbush's "Outperform" rating reflects the analysts' confidence in iTeos Therapeutics' ability to successfully develop and commercialize ITOS-101, as well as its potential for future growth and expansion into new indications.